network member

Masonic Cancer Center, University of Minnesota

420 Delaware Street SE, Minneapolis, MN 55455
Masonic Cancer Center, University of Minnesota

About Network Member

The Masonic Cancer Center was founded in 1991 as the University of Minnesota Cancer Center and received its NCI designation in 1998. It was renamed the Masonic Cancer Center (MCC) in 2009. The Center combines population sciences, basic research, and translational cancer care with community outreach and educational activities. The Center facilitates the research of its members, fosters multidisciplinary approaches to cancer, provides infrastructure support for cancer research, and develops new methods and strategies to reduce cancer incidence and mortality. Prevention, screening, new therapies, biomarker evaluation, functional imaging of cancer, and cancer survivorship are the themes of the work conducted by MCC’s 500+ research members. The major research programs are: Carcinogenesis and Chemoprevention, Cellular Mechanisms, Genetic Mechanisms of Cancer, Immunology; Screening, Prevention, Etiology, and Cancer Survivorship; and Transplant Biology and Therapy. The Center’s clinical research and treatment partners include M Health Fairview and the M Health Fairview University of Minnesota Masonic Children’s Hospital. The Center’s research partners include the University’s Stem Cell Institute, the Center for Immunology, the Center for Magnetic Resonance Imaging, and the Institute of Human Genetics. Specific scientific strengths of MCC include: chemoprevention and carcinogenesis, particularly in tobacco; obesity prevention research; hematopoietic stem cell biology and transplantation, especially in hematologic malignancies; translational research in immune and cell-based therapies; childhood malignancies, including biology, therapy, epidemiology, and survivorship; cancer prevention and screening, especially in colorectal and other solid tumors; immunology; novel mouse models to study cancer center etiology and progression; functional magnetic resonance imaging in cancer; and the development of interventional strategies for cancer prevention and treatment. The Center also takes a leadership role in mission, community interactions, outreach, public relations, and advocacy. Education and outreach programs in the community include involvement with the Minnesota Cancer Alliance/Cancer Plan Minnesota. MCC has also followed up its research in the area of tobacco with an outreach program to advance understanding of tobacco use, addiction, and harm reduction. Website: cancer.umn.edu
Currently Enrolling

BTCRC-HEM15-027

Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM15-027
Cancer areas:Lymphoma
Masonic Cancer Center, University of Minnesota
University of Iowa Holden Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-HN17-111

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
Cancer areas:Head and Neck
Masonic Cancer Center, University of Minnesota
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Cancer areas:Lung
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Moffitt Cancer Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Virginia Commonwealth University
Enrollment Closed

HCRN-MEL16-252

Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Cancer areas:Melanoma
Fox Chase Cancer Center
Masonic Cancer Center, University of Minnesota
Mayo Clinic
Nebraska Cancer Specialists
Providence Cancer Institute
University of Iowa Holden Comprehensive Cancer Center